Sector News

Theranos bleeds dry, company to dissolve: WSJ

September 6, 2018
Life sciences

Theranos, the one-time Silicon Valley biotech star valued at more than $9 billion, has ultimately run out of money, employees and time. It will formally disband in the coming months, according to an email to shareholders obtained by The Wall Street Journal.

Vaulted by failed promises for its simple and comprehensive finger-stick blood test technology, the decision to dissolve the company comes after former CEO Elizabeth Holmes and ex-COO Ramesh “Sunny” Balwani were indicted in June on federal criminal charges of wire fraud and conspiracy.

The company will be liquidated over the next six to 12 months, and plans to dole out its estimated $5 million in remaining cash to its unsecured creditors, according to the email sent out by Theranos General Counsel and CEO David Taylor.

Many of the high-profile investors who backed the company—including media mogul Rupert Murdoch; the Waltons, of Walmart fame; the Cox family behind the Atlanta media company; and Education Secretary Betsy DeVos and her family, all of whom made investments of more than $100 million—will get nothing.

Theranos had been searching for a potential buyer for months, said the WSJ, courting more than 80 suitors with over a dozen entering more formal discussions and deliberations, before coming up empty. This past April, the company laid off most of its employees to avoid bankruptcy. Most of the remaining two dozen workers were let go Aug. 31, with just Taylor and a few support staff left manning their posts.

According to the WSJ, which first investigated Theranos’ business practices and claims beginning in October 2015, the company is set to evaporate after breaching a deal related to a $65 million loan it received last year from Fortress Investment Group to develop a Zika virus assay—which is entitled to foreclose on the company and its assets if its cash dropped too far.

In the email to shareholders, Taylor said Theranos is currently aiming to settle with Fortress, by trading ownership of its patents for being allowed to keep its remaining $5 million, slated for distribution.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.